Briacell Therapeutics Corp (BCTX)

$3.49 -0.01 (-0.29%)
Market Cap 28.36M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 330,269
Avg Vol 213,548
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 75%
Beta 1.15
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
AngelosProject
AngelosProject Jul. 7 at 8:04 PM
$TRNR $BCTX $NAAS charter
0 · Reply
Ares77manoe
Ares77manoe Jul. 7 at 7:53 PM
$BCTX funny to see clowns showing up with their science just after PR...lol
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 7:38 PM
$BCTX
0 · Reply
Orlandotrader
Orlandotrader Jul. 7 at 6:53 PM
$BCTX Lots of Positioning and Market Still a non believer. I like that a lot. Seems to be more Believers here lately. Nice Not talking a Large position here but will Trade this as they Prove Themselves.
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 6:21 PM
$BCTX is already preparing for a potential commercial launch — and Bria-IMT is still in Phase 3 👀 BriaCell just engaged $CRAI and Kaleio to support commercial strategy, market access evaluation, and brand planning for Bria-IMT as its pivotal Phase 3 metastatic breast cancer study continues. ⚕️ The company says this is a commercial-readiness step tied to potential future commercialization planning, pending successful clinical development and regulatory approvals. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38679&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38679
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 5:06 PM
$BCTX BriaCell Therapeutics ($BCTX) Stock Hub: Bria-IMT Phase 3, ASCO 2026, Commercial Readiness and Dilution Risk https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:43 PM
$BCTX BriaCell continues positioning Bria-IMT™ for potential future commercialization, subject to clinical and regulatory success. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:17 PM
$BCTX Kaleio will support brand strategy and commercial-readiness solutions for Bria-IMT™. Another key step forward. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:07 PM
$BCTX news: BriaCell taps Charles River Associates and Kaleio for Bria-IMT™ market access and brand strategy support. NEWS: https://bit.ly/3QK1eTD #Biotech #Oncology #HealthcareInvesting
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:00 PM
$BCTX continues to execute beyond - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6836644
0 · Reply
Latest News on BCTX
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 10 hours ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 11 days ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 12 days ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 12 days ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 12 days ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 6 weeks ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 6 weeks ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 6 weeks ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 6 weeks ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 7 weeks ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 7 weeks ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 7 weeks ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 2 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 2 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 2 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 2 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 2 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 3 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 3 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 3 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 4 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 4 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 4 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 5 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 5 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 5 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Wed, 28 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 5 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Tue, 27 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 6 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

2026-01-16T13:58:57.000Z - 6 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 6 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 6 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 6 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 6 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

2026-01-13T12:35:49.000Z - 6 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 6 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 7 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

2025-12-10T12:41:29.000Z - 7 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

2025-12-09T12:35:35.000Z - 7 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 7 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

2025-12-02T12:36:29.000Z - 7 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 8 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 8 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 8 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 9 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 9 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 11 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 11 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

AngelosProject
AngelosProject Jul. 7 at 8:04 PM
$TRNR $BCTX $NAAS charter
0 · Reply
Ares77manoe
Ares77manoe Jul. 7 at 7:53 PM
$BCTX funny to see clowns showing up with their science just after PR...lol
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 7:38 PM
$BCTX
0 · Reply
Orlandotrader
Orlandotrader Jul. 7 at 6:53 PM
$BCTX Lots of Positioning and Market Still a non believer. I like that a lot. Seems to be more Believers here lately. Nice Not talking a Large position here but will Trade this as they Prove Themselves.
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 6:21 PM
$BCTX is already preparing for a potential commercial launch — and Bria-IMT is still in Phase 3 👀 BriaCell just engaged $CRAI and Kaleio to support commercial strategy, market access evaluation, and brand planning for Bria-IMT as its pivotal Phase 3 metastatic breast cancer study continues. ⚕️ The company says this is a commercial-readiness step tied to potential future commercialization planning, pending successful clinical development and regulatory approvals. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38679&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38679
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 5:06 PM
$BCTX BriaCell Therapeutics ($BCTX) Stock Hub: Bria-IMT Phase 3, ASCO 2026, Commercial Readiness and Dilution Risk https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:43 PM
$BCTX BriaCell continues positioning Bria-IMT™ for potential future commercialization, subject to clinical and regulatory success. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:17 PM
$BCTX Kaleio will support brand strategy and commercial-readiness solutions for Bria-IMT™. Another key step forward. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:07 PM
$BCTX news: BriaCell taps Charles River Associates and Kaleio for Bria-IMT™ market access and brand strategy support. NEWS: https://bit.ly/3QK1eTD #Biotech #Oncology #HealthcareInvesting
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:00 PM
$BCTX continues to execute beyond - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6836644
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 3:38 PM
$BCTX Bria-IMT™ remains in focus as BriaCell advances commercial planning around its metastatic breast cancer program. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply
MikeTechnician
MikeTechnician Jul. 7 at 3:02 PM
$BCTX BriaCell is strengthening its commercial strategy by engaging CRA to evaluate market access, pricing, epidemiology and prescriber dynamics for Bria-IMT™, while bringing on Kaleio to lead brand strategy and commercialization planning. Strategic moves like these can help lay the groundwork for long-term value creation as the company advances its oncology platform. https://globenewswire.com/news-release/2026/07/07/3323056/0/en/briacell-engages-consulting-and-branding-firms-to-support-commercial-and-market-access-evaluation-of-bria-imt.html
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 2:35 PM
BB's Stock Haven : $BCTX today announced that it has engage... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177764889 via @Investors_Hub
0 · Reply
Ares77manoe
Ares77manoe Jul. 7 at 2:29 PM
$BCTX f**** hedgies
0 · Reply
JediGreen
JediGreen Jul. 7 at 2:29 PM
$BCTX
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 2:17 PM
$BCTX today announced that it has engaged Charles River Associates (CRA) (Nasdaq: $CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT. NEWS: https://bit.ly/3QK1eTD #Biotech #Oncology #HealthcareInvesting
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 1:57 PM
$BCTX BriaCell engages CRA and Kaleio to support commercial strategy and market access evaluation for Bria-IMT™. Big commercial-readiness step. https://www.globenewswire.com/news-release/2026/07/07/3323056/0/en/briacell-engages-consulting-and-branding-firms-to-support-commercial-and-market-access-evaluation-of-bria-imt.html
0 · Reply
CAN29
CAN29 Jul. 7 at 1:40 PM
@BioRich FTI Tuesday, 07/07/2026 9:08:05 AM Another positive milestone for $BCTX as BriaCell expands commercial-readiness efforts for Bria-IMT, its Phase 3 metastatic breast cancer immunotherapy candidate.
1 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 1:21 PM
Commercial planning underway at $BCTX. CRA will evaluate market access and pricing potential for Bria-IMT, while Kaleio supports brand strategy. NEWS: https://bit.ly/3QK1eTD #Biotech #Oncology #HealthcareInvesting
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 1:15 PM
BB's Stock Haven : Another positive milestone for $BCTX as BriaCell expands commercial-readiness efforts for Bria-IMT... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177764473 via @Investors_Hub
0 · Reply
BHWinehouse
BHWinehouse Jul. 7 at 1:04 PM
$BCTX Watch list continues to grow
0 · Reply
Biohero
Biohero Jul. 7 at 1:02 PM
$BCTX the stock is absolutely ridiculously cheap, i keep on adding shares. Pipeline for free at 30m$ marketcap. Never seen such an undervalued p3-biotech-stock. Event 144 incoming!
1 · Reply